Cart
sales@molnova.com
WNK463
CAS No. 2012607-27-9
WNK463( WNK-463 | WNK 463 )
Catalog No. M13138 CAS No. 2012607-27-9
The first, potent, selective, and orally bioavailable pan With-No-Lysine (WNK) Kinase catalytic activity inhibitor with IC50 of 5/1/6/9 nM for WNK1/2/3/4.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 131 | In Stock |
|
| 10MG | 192 | In Stock |
|
| 25MG | 326 | In Stock |
|
| 50MG | 484 | In Stock |
|
| 100MG | 699 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWNK463
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe first, potent, selective, and orally bioavailable pan With-No-Lysine (WNK) Kinase catalytic activity inhibitor with IC50 of 5/1/6/9 nM for WNK1/2/3/4.
-
DescriptionThe first, potent, selective, and orally bioavailable pan With-No-Lysine (WNK) Kinase catalytic activity inhibitor with IC50 of 5/1/6/9 nM for WNK1/2/3/4, respectively; shows >50% inhibition against only 2 out of 442 human kinases at 10 uM; affects blood pressure and body fluid and electro-lyte homeostasis in rodent models of hypertension.
-
In VitroWestern Blot Analysis Cell Line:Human tissue-engineered corneas (hTECs)Concentration:50 nM, 1 μΜ, 10 μΜ Incubation Time:6 days Result:Reduced phosphorylation of the WNK1 downstream targets SPAK/OSR1 in wounded hTECs.
-
In VivoAnimal Model:Spontaneously hypertensive Sprague Dawley rats (34-42 weeks of age) Dosage:1 mg/kg, 3 mg/kg, or 10 mg/kg(Pharmacokinetic study)Administration:Oral administration; 4 hours Result:Decreased in blood pressure and simultaneous increases in heart rate. WNK463 produced significant and dose-dependent increased in urine output as well as urinary sodium and potassium excretion rates.
-
SynonymsWNK-463 | WNK 463
-
PathwayAutophagy
-
TargetWNK Kinase
-
RecptorWNK
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number2012607-27-9
-
Formula Weight463.4562
-
Molecular FormulaC21H24F3N7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 30 mg/mL
-
SMILESO=C(C1=CN=CN1C2CCN(C3=NC=C(C4=NN=C(C(F)(F)F)O4)C=C3)CC2)NC(C)(C)C
-
Chemical Name1H-Imidazole-5-carboxamide, N-(1,1-dimethylethyl)-1-[1-[5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-2-pyridinyl]-4-piperidinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yamada K, et al. Nat Chem Biol. 2016 Nov;12(11):896-898.
2. Zhang J, et al. Sci Signal. 2016 Oct 18;9(450):pe3.
molnova catalog
related products
-
WNK463
The first, potent, selective, and orally bioavailable pan With-No-Lysine (WNK) Kinase catalytic activity inhibitor with IC50 of 5/1/6/9 nM for WNK1/2/3/4.
-
WNK inhibitor 7
A potent, selectiive inhibitor of WNK1 kinase with IC50 of 95 nM, shows IC50 of 1.39 uM in the cellular OSR1 phosphorylation assay with reasonable aqueous solubility.
-
WNK inhibitor 11
WNK inhibitor 11 is a potent, selectiive and orally active inhibitor of WNK1 kinase with IC50 of 6 nM, 1,000-fold selectivity over WNK4 and 57-fold selectivity over WNK2.
